Post by Shamroz H.

Helping Public Companies Reach a Wider Audience | Investor Awareness & Telemarketing Outreach | Market Visibility & Volume Growth

Big news in biotech: uniQure N.V. (NASDAQ: #QURE) has announced positive topline results from its pivotal Phase I/II trial of AMT-130, a gene therapy candidate for Huntington’s disease. Key Highlights: AMT-130 demonstrated a meaningful slowing of disease progression compared to a matched natural history cohort. Clinical benefits observed across multiple functional and imaging endpoints. The therapy was generally well-tolerated. uniQure plans to initiate Phase III planning in 2026. This marks a major milestone in the pursuit of a potential disease-modifying treatment for a devastating neurodegenerative disorder. Huntington’s disease currently has no cure; this advancement offers hope to patients and families worldwide. https://lnkd.in/dHfNWGeQ

Post content